CAR-T Companies Hang Onto Novartis' Coat-Tails After Historic FDA Panel Vote

The FDA panel landmark recommendation for Novartis' CTL019 should provide a fillip for the other players in the CAR-T field but the response from the investment community has been lukewarm compared with researchers and patients.